{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:34:47Z","timestamp":1791466487556,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jacl.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T12:45:18Z","timestamp":1486730718000},"page":"450-458.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels"],"prefix":"10.1016","volume":"11","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sartipy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Underberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.01.018_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National Lipid Association Annual Summary of Clinical Lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.018_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.01.018_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2017.01.018_bib4","first-page":"S1","article-title":"Standards of medical care in diabetes 2016","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.01.018_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/157016112803520864","article-title":"Mechanisms of diabetic dyslipidemia: relevance for atherogenesis","volume":"10","author":"Arca","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacl.2017.01.018_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-001-0006-y","article-title":"Diabetes: statins, fibrates, or both?","volume":"3","author":"Farnier","year":"2001","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2017.01.018_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s13300-016-0167-x","article-title":"Diabetes dyslipidemia","volume":"7","author":"Schofield","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacl.2017.01.018_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4065\/mcp.2010.0058","article-title":"To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?","volume":"85","author":"Lavie","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2017.01.018_bib9","series-title":"Dyslipidemias","first-page":"99","article-title":"Type 2 diabetes and dyslipidemia","author":"Cederberg","year":"2015"},{"key":"10.1016\/j.jacl.2017.01.018_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13300-013-0042-y","article-title":"Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus","volume":"4","author":"Bays","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacl.2017.01.018_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/03007990802710422","article-title":"From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus","volume":"25","author":"Bays","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2017.01.018_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2017.01.018_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/dia.2013.0167","article-title":"Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin","volume":"16","author":"Mudaliar","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jacl.2017.01.018_bib14","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.01.018_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2017.01.018_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2017.01.018_bib17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.018_bib18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.01.018_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.01.018_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.01.018_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14740338.2016.1195368","article-title":"Cardiovascular effects of anti-diabetes drugs","volume":"15","author":"Younk","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacl.2017.01.018_bib22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.018_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2017.01.018_bib24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2017.01.018_bib25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.01.018_bib26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.01.018_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2013a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.01.018_bib28","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2017.01.018_bib29","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.01.018_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.01.018_bib31","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.01.018_bib32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.01.018_bib33","doi-asserted-by":"crossref","first-page":"520465","DOI":"10.1155\/2008\/520465","article-title":"Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies","volume":"2008","author":"Deeg","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.jacl.2017.01.018_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417300235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417300235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:25:03Z","timestamp":1536045903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417300235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1933287417300235"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.01.018","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}